About Us
Taizhou BioAlly Biotechnology Co., Ltd. relocated from Beijing to China Medical City in 2018, with a registered capital of over 58.2 million RMB. It is a national high-tech enterprise in China exclusively dedicated to the R&D, production and sales of innovative pet pharmaceuticals including biological products, traditional Chinese veterinary medicines and chemical synthetic drugs, as well as third-party pet health testing services. The company has been awarded numerous authoritative honors, such as Jiangsu Provincial Science and Technology Innovation Little Giant Enterprise, Jiangsu Provincial Sci-Tech Small and Medium-sized Enterprise, and Jiangsu Provincial Gazelle Enterprise. It is also recognized as a Talent Innovation & Entrepreneurship Enterprise by the Organization Department of Jiangsu Provincial Party Committee. Furthermore, BioAlly operates as the settled institution of Taizhou Offshore Innovation Center, Taizhou Engineering Research Center for Innovative Pet Drugs, and Taizhou Engineering Technology Research Center for Innovative Pet Drugs. As the only enterprise in China’s pet industry serving concurrently as Vice Chairman Unit of the Pet Diagnosis and Treatment Branch of the Chinese Veterinary Medical Association and Vice Chairman Unit of the Pet Industry Branch of the China Animal Agriculture Association, BioAlly holds a core position in the industry and facilitates the integration of China’s pet animal health industry into the global development landscape.
Figure 1: On-site photo of the company
To accelerate the global industrialization of new products, the company has invested over 280 million RMB in constructing a full-functional R&D and production campus for pet health in accordance with EU standards. Covering a land area of 31 mu (about 20,666 square meters) with a building area of 24,000 square meters, the campus consists of a GMP production building for biological products, a GMP production building for new pharmaceutical formulations, a production building for functional health products, and a production building for sanitary disinfection supplies.
It is fully equipped with supporting facilities for R&D and quality inspection, animal experiments, office operation and environmental protection. In July 2023, the campus officially commenced production after obtaining a full range of domestic and international core certifications, including CNAS laboratory accreditation, GCP for veterinary drugs and biological products, as well as GMP certification for chemical and traditional Chinese veterinary medicines and biological products.
With complete qualifications for R&D and production in the global pet animal health sector, BioAlly has established a solid foundation for global product sales and international market services.
Figure 2: Aerial view of the company campus
With over a decade of in-depth dedication to R&D and innovative breakthroughs, BioAlly has built four world-leading core biopharmaceutical R&D and production platforms: Pathogen Isolation, Identification and Testing Platform, GCP-compliant Animal Experiment Platform, Cell Engineering Platform, and Genetic Engineering Platform.
To date, the company has obtained 9 New Veterinary Drug Certificates (including 1 globally pioneering Class I New Veterinary Drug and 4 nationally pioneering Class II New Veterinary Drugs), 7 clinical approvals for biological products, and 18 invention patents (17 in China and 1 in the United States). Another 22 pipelines are under registration for new veterinary drug approval. The product pipeline features global pioneering value and technological uniqueness. Empowered by strong independent innovation capabilities, BioAlly has built solid technological barriers and core competitiveness for the global market, driving the implementation of its globalization strategy and continuous market expansion.
BioAlly’s core competence lies in the R&D of pet biological products. The company has established three professional platforms for recombinant protein drug development: E. coli recombinant expression platform, Pichia pastoris recombinant expression platform, and CHO cell expression platform. Multiple products from the three platforms have either obtained national new veterinary drug registration approval or are currently undergoing registration procedures. In the field of innovative pet pharmaceuticals, BioAlly has achieved original innovation from scratch and domestic substitution from scale-up, with a number of core products reaching world-leading standards. Its forward-looking product pipeline is reshaping the competitive landscape of the global pet biopharmaceutical industry.
1.In December 2023, BoShengJian® Canine Human Albumin Injection, the world’s first Class I New Veterinary Drug, was approved for marketing, filling the global gap in technical research and product supply in the corresponding pet health segment.
2.In January 2024, MiaoBeiHu® RCP Feline Triple Vaccine obtained the first provisional approval issued by the Ministry of Agriculture and Rural Affairs. It was officially granted the Class II New Veterinary Drug Certificate in July 2025, making it China’s first feline triple vaccine approved via national new veterinary drug registration. Boasting four core competitive advantages, it adopts superior local strains for comprehensive immune protection, applies high-tech nano-water adjuvant for faster immune response, breaks through core culture and purification technologies to ensure superior product safety, and implements EU-standard production facilities for precise quality control. As of February 4, 2026, the product has reached a batch release volume of 4.29 million doses, covering over 10,000 offline pet stores and more than 3,000 high-end catteries nationwide. With a market share exceeding 20% in 2025, it ranks first among domestic brands and is increasingly competitive against international mainstream brands.
3.On September 16, 2025, MiaoBeiJian® Recombinant Feline Omega Interferon was certified as a Class II New Veterinary Drug. It is the first approved product of its kind in China and the second worldwide, as well as the world’s first dual-purpose interferon for both injection and eye drops, creating new application scenarios for pet interferon globally. With a series of original innovative achievements, BioAlly leads the historic leap of China’s pet pharmaceutical industry from zero to independent breakthroughs, continuously enhancing China’s voice and influence in the global pet animal health industry.
4.On July 7, 2025, Maropitant Citrate Injection became China’s first officially registered Class II New Veterinary Drug in its category.
5.On November 23, 2025, Pigeon Newcastle Disease Inactivated Vaccine (Strain PN06) was approved as China’s first Class II New Veterinary Drug in its segment.
Figure 3: Media coverage of BioAlly in 2025
Adhering to the development tenet of Building Brand with Quality, Creating Extraordinary from Ordinary and the core values of Self-motivation, Self-discipline, Co-creation and Shared Benefits, BioAlly operates based in China with a global vision and actively fulfills corporate social responsibilities as a global enterprise. Through special honor and talent support programs including the BioAlly Outstanding Young Veterinarian Award, Distinguished Veterinarian Award, Most Beautiful Veterinarian Award, as well as BioAlly Scholarship and Teaching Grants, the company builds a bridge for international veterinary talent cultivation and exchanges, empowering the professional growth of global pet medical practitioners. Today, BioAlly has grown into a benchmark brand in the domestic and international pet healthcare industry. It not only promotes the technological upgrading and social influence of China’s pet diagnosis and treatment industry, but also facilitates the alignment of China’s pet medical cause with international cutting-edge standards and global development vision, safeguarding the health and well-being of pets worldwide with professional expertise.